Khaled Musallam/LinkedIn
Aug 13, 2026, 11:05
Khaled Musallam: The Evolving Landscape of β-Thalassemia: Clinical Trial Advances Since 2021
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in American Journal of Hematology, adding:
“Pleased to share our latest ‘2026 Update on Clinical Trials in β-Thalassemia,’ published today in the American Journal of Hematology.
It is incredibly fulfilling to reflect on how much the field has advanced since our last update in 2021 with new approvals and an expanding pipeline continuing to reshape the treatment landscape for β-thalassemia.”
Title: 2026 Update on Clinical Trials in β-Thalassemia
Authors: Khaled M. Musallam, Franco Locatelli, Mattia Algeri, Maria Domenica Cappellini, Ali T. Taher
Stay updated with Hemostasis Today.
-
Aug 13, 2026, 12:48Annie Bauzon: Understanding the Genetics of Hemophilia
-
Aug 13, 2026, 11:15Bridging Neurology and Thrombosis: Key Priorities from a New Expert Consensus Report – International Journal of Stroke
-
Aug 13, 2026, 10:31Brad Wilson: Clinical Insights from the Landmark ESC 2026 Trials
-
Aug 13, 2026, 10:23Rania Baleela: Evaluating Bedside Diagnostics and VICC Outcomes in Hemotoxic Snakebite
-
Aug 13, 2026, 10:11Christina Kounoudi: Low-Dose vs. Therapeutic Anticoagulation in Extended VTE Prophylaxis
-
Aug 13, 2026, 10:10Jean Connors: Can Prothrombin Levels Improve Antiphospholipid Syndrome Risk Assessment?
-
Aug 13, 2026, 09:44Edward Lee Carter: Why Clinically Relevant Nonmajor Bleeding Demands Anticoagulation Stewardship?
-
Aug 13, 2026, 09:40Neel Bhut: Can AI Help Us Make Gene Therapy More Efficient?
-
Aug 13, 2026, 08:23Sally Mandour: The Diagnostic Challenge of Hypocellular Bone Marrow Failure